Early Detection Research Network

Farlow 6-marker panel for Lung Cancer

Aliases:
This biomarker is also known as:
  • Farlow 6-marker panel for Lung Cancer,

Description…

This study aimed to develop a serum test that could be used to discern NSCLC patients from cancer-free controls and may provide a means to indicate who should have spiral CT done. A large number of potential tumor autoantibodies for NSCLC were identified and validated. The six-analyte blood test that resulted from this study (consisting of IMPDH, phosphoglycerate mutase, ubiquilin, Annexin I, Annexin II, and HSP70-9B) possessed excellent test performance characteristics when tested against our 196 patient cohort that was composed of four clinically distinct groups, with only 13 patients misclassified overall.

Datasets

There are no datasets associated with this biomarker.

Attributes
QA State: Curated
HGNC Name:

Panel Details

The following organs have data associated with this biomarker…

Attributes

Phase: Two
QA State: Curated

Overview

This study aimed to develop a serum test that could be used to discern NSCLC patients from cancer-free controls and may provide a means to indicate who should have spiral CT done. A large number of potential tumor autoantibodies for NSCLC were identified and validated. The six-analyte blood test that resulted from this study (consisting of IMPDH, phosphoglycerate mutase, ubiquilin, Annexin I, Annexin II, and HSP70-9B) possessed excellent test performance characteristics when tested against our 196 patient cohort that was composed of four clinically distinct groups, with only 13 patients misclassified overall.

Performance Comment

A CART analysis fashioned from these six analytes was used to define a specific algorithm for classifying patients according to NSCLC disease status. This algorithm provided excellent ROC parameters for the overall study, including an AUC of 0.964, a sensitivity of 94.8%, and a specificity of 91.1%. The overall misclassification rate was 7% against the entire patient population (n = 196). The general agreement of the results yielded by the two multivariate algorithms (i.e., random forest and CART) serves as an ad hoc “internal confirmation” for the specific six analytes selected by each method and generates confidence in our methods.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.

No other associated resources found.